У нас вы можете посмотреть бесплатно AxoGen (AXGN): FDA-Backed Nerve Repair Innovation & Growth Strategy | Three North Partners или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
In this episode of SumZero, we host Mark Buckley and Augie Hong, co-founders of Three North Partners, for a deep-dive into AxoGen (NASDAQ: AXGN) – a pioneering small-cap medtech company transforming peripheral nerve repair. Buckley and Hong share their investment thesis on AxoGen, including: 1. Market opportunity in an estimated multi‑billion‑dollar nerve repair segment 2. Technology differentiation, including cadaver-sourced nerve grafts and FDA-cleared solutions 3. Competitive landscape and AxoGen’s position versus standard of care 4. Financial profile and growth trajectory, with key milestones and regulatory catalysts ahead 5. How Three North Partners integrates under-the-radar small-cap opportunities like AxoGen into a broader investment strategy For institutional investors, this session is a chance to understand both the innovation platform driving AxoGen’s growth and the disciplined investment approach Three North Partners uses to identify asymmetric return opportunities. Timestamps: 00:00 – Guest Introductions 01:23 – Three North Partners: Founding & Philosophy 02:32 – Investment Strategy & AxoGen Overview 04:35 – AxoGen’s Market & Product Details 18:37 – Competitive Landscape 22:45 – Financials & Growth Projections 25:34 – FDA Approvals & Future Prospects 40:48 – Closing Takeaways